Efrat Kunik - Orgenesis Chief Officer
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Insider
Efrat Kunik is Chief Officer of Orgenesis
| Age | 49 |
| Phone | 480 659 6404 |
| Web | https://orgenesis.com |
Orgenesis Management Efficiency
The company has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2725) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.Orgenesis currently holds 22.62 M in liabilities with Debt to Equity (D/E) ratio of 0.64, which is about average as compared to similar companies. Orgenesis has a current ratio of 1.54, which is within standard range for the sector. Debt can assist Orgenesis until it has trouble settling it off, either with new capital or with free cash flow. So, Orgenesis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orgenesis sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orgenesis to invest in growth at high rates of return. When we think about Orgenesis' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Aseem Ansari | Design Therapeutics | N/A | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| Daniella CPA | Tango Therapeutics | 45 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| LLM JD | Rezolute | 63 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| MD Kaelin | Tango Therapeutics | 66 | |
| Brian MD | Rezolute | 49 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| John MD | Lixte Biotechnology Holdings | 87 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
Management Performance
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 |
Orgenesis Leadership Team
Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Victor Miller, Chief Officer | ||
| Osher Rheinisch, General Officer | ||
| Neil CPA, S CFO | ||
| Shimon Hassin, Chief Officer | ||
| Efrat Kunik, Chief Officer | ||
| Pierre Lammeretz, Interim Officer | ||
| Evan Fishman, Chief Officer | ||
| Joseph Carpinelli, Chief Octomera | ||
| Dan Slonim, COO Israel | ||
| Vered MSc, CEO Board | ||
| Pr Ferber, Founder Officer | ||
| Vincent Vandamme, VP Strategy |
Orgenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Shares Owned By Insiders | 21.16 % | ||||
| Shares Owned By Institutions | 4.54 % | ||||
| Number Of Shares Shorted | 56.25 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |